论文部分内容阅读
[目的]探讨年轻局部晚期乳腺癌的临床病理特点、新辅助治疗的疗效和影响疗效的相关因素。[方法]回顾性分析中国医学科学院肿瘤医院2005年1月至2009年1月收治的年龄小于40岁的接受术前化疗的局部晚期乳腺癌患者资料。[结果]全组患者病理完全缓解9例(13.0%),有效率76.8%(53/69);1例病情进展。5例在化疗后接受了保乳手术。单因素分析发现,含紫杉类方案(TE)是影响新辅助化疗疗效因素(P<0.05),而组织学分级,肿瘤大小,淋巴结状况,ER、PR、HER-2表达和分子分型与新辅助化疗疗效无关。[结论]年轻局部晚期乳腺癌对术前化疗敏感,含紫杉类药物的方案有助于提高化疗疗效。
[Objective] To investigate the clinicopathological characteristics of young locally advanced breast cancer, the efficacy of neo-adjuvant therapy and the related factors that affect the curative effect. [Methods] The data of patients with locally advanced breast cancer undergoing preoperative chemotherapy less than 40 years of age from January 2005 to January 2009 in Cancer Hospital of Chinese Academy of Medical Sciences were retrospectively analyzed. [Results] All the patients had complete remission in 9 cases (13.0%), the effective rate was 76.8% (53/69), and 1 patient’s disease progressed. Five patients underwent breast-conserving surgery after chemotherapy. Univariate analysis showed that TE containing TE was the most influential factor in neoadjuvant chemotherapy (P <0.05), while histological grade, tumor size, lymph node status, ER, PR, HER-2 expression and molecular typing Neoadjuvant chemotherapy has nothing to do. [Conclusion] The young locally advanced breast cancer is sensitive to the preoperative chemotherapy. The regimen containing the taxane can help to improve the curative effect of chemotherapy.